Methods used by WHO to estimate the global burden of TB disease

24 November 2022

Glaziou P¹, Arinaminpathy N², Dodd P.J.³, Dean A¹, Floyd K¹

1. Global TB Programme, World Health Organization, Geneva, Switzerland
2. MRC Centre for Global Infectious Disease Analysis, Imperial College London, United Kingdom
3. School of Health and Related Research, University of Sheffield, United Kingdom

Abstract

This technical appendix describes methods used by WHO in 2022 to estimate the following: tuberculosis (TB) incidence and mortality for the period 2000–2021; TB incidence and mortality disaggregated by age and sex for 2021; proportion of TB cases with rifampicin-resistant (RR) TB, which includes multidrug-resistant (MDR) TB (together referred to as MDR/RR-TB), and incidence of MDR/RR-TB for the period of 2015-2021; mortality due to MDR/RR-TB in 2021; proportion of MDR/RR-TB cases with fluoroquinolone resistance (pre-extensively drug-resistant TB, pre-XDR-TB) in 2021; number of deaths averted by TB interventions from 2000-2021; number of household contacts of bacteriologically confirmed pulmonary TB cases aged under 5 years and eligible for TB preventive therapy (TPT) in 2015-2021; and attributable risk for TB in 2021.

Four main methods are used to derive incidence over the period 2000-2019: (i) results from TB prevalence surveys; (ii) notifications in high-income countries adjusted by a standard factor to account for under-reporting and underdiagnosis and (iii) national inventory studies; (iv) case notification data combined with expert opinion about case detection gaps. Mortality is obtained from national vital registration systems of mortality surveys, where available. In other countries, mortality is derived indirectly from incidence and case fatality ratio.

For the years 2020 and 2021, TB incidence and mortality are estimated using dynamic models for 28 countries. Such models were used for countries with large absolute reductions in the reported number of people newly diagnosed with TB in 2020 or 2021 (case notifications) relative to pre-
2020 trends; these reductions were interpreted as being due to reduced detection of people with TB. Although individual countries may have reported large relative reductions in case notifications, in absolute terms these reductions may not have been sufficient to warrant their inclusion in the country-specific modelling described above. Instead, region-specific models were used for 26 countries that reported a cumulative reduction in TB case notifications of 10% or more in 2020 to 2021 inclusive, relative to pre-2020 trends.

Estimates of TB incidence and mortality in all high-income countries in 2020 and 2021 were produced using the same methods as those used pre-2020; that is, notification data with a standard adjustment for incidence, and vital registration (VR) data for mortality. For low- and middle-income countries (LMIC) that were not modelled (i.e. those for which case notifications in 2020 and 2021 did not show a substantial reduction relative to pre-2020 trends), the methods used to estimate TB incidence and mortality before 2020 were retained for use in 2020 and 2021, with the assumption that pre-2020 trends continued in 2020 and 2021.

Previous Global TB Reports included estimates of the incidence of MDR/RR-TB for the latest calendar year only. New methods were developed in 2022 to allow the production of time series of estimates for the period 2015–2021. The time series are for the absolute number of incident MDR/RR-TB cases and the proportions of TB cases (new and previously treated) that have MDR/RR-TB.

Code for implementing the described methods is available in a public repository.
1. Introduction

Estimates of the burden of disease caused by TB and measured in terms of incidence, prevalence and mortality are produced annually by WHO using information gathered through surveillance systems (case notifications and death registrations), special studies (including surveys of the prevalence of disease), mortality surveys, “inventory studies” of under-reporting of detected TB, in-depth analysis of surveillance and other data, expert opinion and consultations with countries. In June 2006, the WHO Task Force on TB Impact Measurement was established,[1] to ensure robust, rigorous and consensus-based assessment of progress towards milestones and targets for reductions in TB disease. The Task Force reviewed methods and provided recommendations in 2008, 2009, 2015, 2016, 2019 and most recently in May 2022.

Code for implementing the described methods is available in a public repository.

2. Historical background

Historically, a major source of data to derive incidence estimates were results from tuberculin surveys conducted in children.[2] Early studies showed the following relationship between the annual risk of infection denoted $\lambda$ and the incidence of smear positive TB denoted $I_{S+}$: one smear positive case infects on average 10 individuals per year for a period of 2 years and a risk of infection of $10^{-2} y^{-1}$ corresponds approximately to an incidence rate of $50 \times 10^{-5} y^{-1}$. However, this relationship no longer holds in the context of modern TB control and in settings with a high prevalence of HIV.[3] In addition to uncertainty about the relationship between $\lambda$ and $I_{S+}$, estimates of incidence obtained from tuberculin surveys suffer from other sources of uncertainty and bias, including unpredictable diagnostic performance of the tuberculin test,[4] digit preference when reading and recording the size of tuberculin reactions,[5] sensitivity to assumptions about reaction sizes attributed to infection,[6] sensitivity to the common assumption that the annual risk of infection is age invariant, and lastly, sensitivity of overall TB incidence estimates to the assumed proportion of TB incidence that is smear positive.

A first global and systematic estimation exercise led by WHO in the early 1990s estimated that there were approximately 8 million incident TB cases in 1990 ($152 \times 10^{-5} y^{-1}$) and 2.6-2.9 million
A second major reassessment was published in 1999,[8] with an estimated 8 million incident cases for the year 1997 ($136 \times 10^{-5} y^{-1}$), and 1.9 million TB deaths ($32 \times 10^{-5} y^{-1}$). The most important sources of information were case notification data for which gaps in detection and reporting were obtained from expert opinion. In addition, data from 24 tuberculin surveys were translated into incidence and 14 prevalence surveys of TB disease were used.
3. Incidence of TB, 2000-2019

TB incidence has never been measured through population based surveys at the national level because this would require long-term studies among large cohorts of people (hundreds of thousands of people), involving high costs and challenging logistics. Notifications of TB cases provide a good proxy indication of TB incidence in countries that have both high-performance surveillance systems (where there is little under-reporting of diagnosed cases) and where the quality of and access to health care means that few cases remain undiagnosed and overdiagnosis is limited. In the large number of countries where these criteria are not yet met, better estimates of TB incidence can be obtained from an inventory study. An inventory study aims at quantifying the level of under-reporting of detected TB cases; if certain conditions are met, capture-recapture methods can also be used to estimate TB incidence.[9]

The ultimate goal of TB surveillance is to directly measure TB incidence from national case notifications in all countries. This requires a combination of strengthened surveillance, better quantification of under-reporting and over-reporting (i.e. the number of newly diagnosed cases that are missed by surveillance systems and the number of cases over-diagnosed with TB) and universal access to quality health care (to minimize under-diagnosis of cases and overdiagnosis). A TB surveillance checklist developed by the WHO Global Task Force on TB Impact Measurement defines the standards that need to be met for notification data to provide a direct measure of TB incidence.[10]

Methods currently used for the period 2000-2019 by WHO to estimate TB incidence can be grouped into four major categories. The distribution of countries according to the four categories are shown in Figure 2.111 of the web content of WHO’s Global TB Report 2022 - in reality, methods are often combined to estimate the entire time series and the distribution of countries shown reflects the main method used to estimate incidence over the most recent years up to 2019.

1. **Results from TB prevalence surveys.** Incidence is estimated using prevalence survey results and estimates of the distribution characteristics of duration of disease, accounting for the impact of HIV coinfection and antiretroviral therapy (ART). This method is used for 29 countries, of which 28 have national survey data and one – India – has a survey in one state. The 29 countries accounted for 66% of the estimated global number of incident cases in 2019.
2. **Notifications in high-income countries adjusted by a standard factor to account for under-reporting, under-diagnosis and overdiagnosis/overreporting.** This method is used for 139 countries that comprise all high-income countries except Germany, the Netherlands and the United Kingdom, plus selected upper-middle income countries with low levels of underreporting, including Brazil, China and the Russian Federation. For three countries (France, Republic of Korea and Turkey) the adjustment was country specific, based on results from reports of underreporting. These 139 countries accounted for 6% of the estimated global number of incident cases in 2019.

3. **Results from inventory/capture-recapture studies.** This method is used for 8 countries: China, Egypt, Germany, Indonesia, Iraq, the Netherlands, the United Kingdom and Yemen. They accounted for 17% of the estimated global number of incident cases in 2019.

4. **Case notification data combined with expert opinion about case detection gaps.** Expert opinion, elicited in regional workshops or country missions, is used to estimate levels of under-reporting and under-diagnosis. Trends are estimated using either mortality data, surveys of the annual risk of infection or exponential interpolation using estimates of case detection gaps for three years. This method is considered generally unreliable and used when other methods are not applicable due to missing or poor quality data. In this report, this method is used for 39 countries that accounted for 11% of the estimated global number of incident cases in 2019.

**Four main methods**

**Method 1 - Case notification data combined with expert opinion about case detection gaps**

Expert opinion, elicited in regional workshops, national consensus workshops or country missions, is used to estimate levels of under-reporting, over-reporting (false positive diagnoses that may occur particularly in the context of systematic screening in populations with relatively low probability of TB disease) and under-diagnosis. Trends are estimated using either mortality data, national repeat surveys of the annual risk of infection or exponential interpolation using estimates of case detection gaps for specific years. The estimation of case detection gaps is essentially based
on an in-depth analysis of surveillance data; experts provide their educated best guess about the range of the plausible detection gap $g$ and incidence $I$ is obtained from

$$I = \frac{f(N)}{I - g}, \quad g \in [0, I]$$

where $N$ denotes case notifications, $f$ denotes a cubic spline function in countries with large year-to-year fluctuations in $N$, or else, the identity function. The incidence series are completed using assumptions about changes in case fatality rate (CFR) over time in countries with evidence of improvements in TB prevention and care, such as increased detection coverage over time or improved treatment outcomes, ensuring that the following inequality holds

$$0 \leq \frac{\Delta I}{\Delta t} \leq \frac{\Delta M}{\Delta t}$$

where $M$ denotes mortality.

A full description of the methods used in regional workshops where expert opinion was systematically elicited following an in-depth analysis of surveillance data is publicly available in a report of the workshop held for countries in the African Region (in Harare, Zimbabwe, December 2010).[11] In some countries, case reporting coverage changed significantly during the period 2000-2019 as a result of disease surveillance reforms. Trends in incidence are derived from repeat tuberculin survey results in Bhutan, India and Yemen and from trends in mortality or case notifications.

Case proportions are assumed to follow a beta distribution, with parameters $\alpha$ and $\beta$ obtained from the expected value $E$ and variance $V$ using the method of moments, as follows

$$\alpha = E \left( \frac{E(1-E)}{V} - 1 \right)$$

$$\beta = (1 - E) \left( \frac{E(1-E)}{V} - 1 \right)$$

Time series are built according to the characteristics of the levels of under-reporting and under-diagnosis that were estimated for specific reference years (three reference years in regional workshops conducted around 2010). A cubic spline extrapolation of $V$ and $E$, with knots set at the reference years, is used for countries with low-level or concentrated HIV epidemics. In countries
with a generalized HIV epidemic, the trajectory of incidence is based on the annual rate of change in HIV prevalence and time changes in the fraction $F$ of incidence attributed to HIV, determined as follows

$$F = \frac{h(\rho - 1)}{h(\rho - 1) + 1} = \frac{\vartheta - h}{1 - h}$$

where $h$ is the prevalence of HIV in the general population, $\rho$ is the TB incidence rate ratio among HIV-positive individuals over HIV-negative individuals and $\vartheta$ is the prevalence of HIV among new TB cases.

If there is insufficient data to determine the factors leading to time-changes in case notifications, incidence is assumed to follow a horizontal trend going through the most recent estimate of incidence.

Limitations of the method based on eliciting expert opinion about gaps in case detection and reporting include a generally small number of interviewed experts; lack of clarity about vested interests when eliciting expert opinion; lack of recognition of over-reporting (due to over-diagnosis, e.g. in some countries implementing a large-scale systematic population screening policy that may result in many people with abnormal chest X-ray but no bacteriological confirmation of TB disease being notified and treated as new TB cases) or in countries where cases with confirmed non-TB mycobacteria were not systematically reviewed and those judged non-TB were not de-notified; incomplete data on laboratory quality and high proportion of patients with no bacteriological confirmation of diagnosis are a potential source of error in estimates.

**Method 2 - Results from TB prevalence surveys**

Two approaches were used to derive incidence from prevalence.

In a first approach, incidence is estimated using measurements from national surveys of the prevalence of TB disease combined with estimates of the duration of disease. Incidence is estimated as the prevalence of TB divided by the average duration of disease assuming epidemic equilibrium: let $N$ denote the size of a closed population with the number of birth and deaths the same for a period $\Delta t>0$, let $C$ be the number of prevalent TB cases, $P$ the prevalence rate so that $P=C/N$. Let $m$ denote the rate of exit from the pool of prevalent cases through mortality, spontaneous self-cure or cure from treatment, and $I$ the rate at which new cases are added to the
pool. At equilibrium during the time period $\Delta t$ and further assuming exponentially distributed durations $d$ such that $d = \frac{m}{I}$

$$I(N - C) = mC$$

$$I = \frac{mc}{N - C} = \frac{p}{d(I - p)} \approx \frac{p}{d}$$

In practice, the average duration of presence in the pool of prevalent cases cannot be directly measured. For example, measurements of the duration of symptoms in prevalent TB cases that are detected during a prevalence survey are systematically biased towards lower values, since survey investigations truncate the natural history of undiagnosed disease. Measurements of the duration of disease in notified cases ignore the duration of disease among non-notified cases and are affected by recall biases.

Literature reviews have provided estimates of duration of disease in untreated TB cases from the pre-chemotherapy era (before the 1950s). The best estimate of the mean duration of untreated disease (for smear-positive and smear-negative cases combined) in HIV-negative individuals is about three years. There are few data available on the duration of disease in HIV-positive individuals. The assumed distributions of disease durations are shown in Table 1.

**Table 1. Distribution of disease duration by case category**

<table>
<thead>
<tr>
<th>Case category</th>
<th>Distribution of disease duration (year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated, HIV-negative</td>
<td>Uniform (0.2–2)</td>
</tr>
<tr>
<td>Not treated, HIV-negative</td>
<td>Uniform (1–4)</td>
</tr>
<tr>
<td>Treated, HIV-positive</td>
<td>Uniform (0.01–1)</td>
</tr>
<tr>
<td>Not treated, HIV-positive</td>
<td>Uniform (0.01–0.2)</td>
</tr>
</tbody>
</table>
A second approach consists of estimating disease duration using three compartments: susceptibles \((S)\), untreated for TB \((U)\) and treated for TB \((T)\). The size of \(U\) and \(T\) is obtained from the results of the prevalence survey. Transition rates from \(U\) to \(T\) are determined as follows

\[
\frac{dU}{dt} = IS - (\mu_u + \theta_u + \delta)U
\]

\[
\frac{dT}{dt} = \delta U - (\mu_t + \theta_t)T
\]

Where \(I\) denotes Incidence, \(\mu\) and \(\theta\) denote mortality and self-cure (remission) or cure (with subscripts \(u\) and \(t\) indicating untreated and treated cases), respectively, \(\delta\) denotes the rate of removal from \(U\) through detection and treatment. At equilibrium, the above two equations simplify to

\[
I = \frac{U}{d_U}
\]

\[
\delta U = \frac{T}{d_T}
\]

Disease duration (untreated) is obtained from

\[
d_U = (1 - \pi) \frac{U}{T} d_T
\]

where

\[
\pi = 1 - \frac{\delta U}{IS}
\]

is the proportion of incidence that dies or self-cures before treatment. \(\pi\) is assumed to be a distributed uniform with bounds 0 and 0.05[12]. Table 2 shows estimates of incidence from four prevalence surveys using this method.
Table 2. Incidence estimation based on $U/T$

<table>
<thead>
<tr>
<th></th>
<th>$U$ (n)</th>
<th>$T$ (n)</th>
<th>Prevalence $(10^{-3})$</th>
<th>Duration (year)</th>
<th>Incidence $(10^{-3}y^{-1})$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambodia 2002</td>
<td>260</td>
<td>42</td>
<td>12 (10-15)</td>
<td>2.9 (1.9-4)</td>
<td>4 (2.5-5.8)</td>
</tr>
<tr>
<td>Cambodia 2011</td>
<td>205</td>
<td>80</td>
<td>8.3 (7.1-9.8)</td>
<td>1.2 (0.8-1.6)</td>
<td>6.7 (4.5-9.3)</td>
</tr>
<tr>
<td>Myanmar 2009</td>
<td>300</td>
<td>79</td>
<td>6.1 (5-7.5)</td>
<td>1.8 (1.1-1.6)</td>
<td>3.3 (2-4.8)</td>
</tr>
<tr>
<td>Thailand 2012</td>
<td>136</td>
<td>60</td>
<td>2.5 (1.9-3.5)</td>
<td>1.1 (0.5-1.6)</td>
<td>2.3 (1-3.5)</td>
</tr>
</tbody>
</table>

Limitations of this method include the insufficient power of disease prevalence surveys to estimate the number of prevalent TB cases on treatment with sufficient precision. Further, in most surveys, cases found on treatment during the survey do not have a bacteriological status at onset of treatment documented based on the same criteria as survey cases (particularly when culture or Xpert were not performed routinely). The method, however, provides more robust estimates of incidence compared with those obtained from expert opinion (method 1).

In countries with high-level HIV epidemics that completed a prevalence survey, the prevalence of HIV among prevalent TB cases was found systematically lower than the prevalence of HIV among newly notified TB cases, with an HIV prevalence rate ratio among prevalent TB over notified cases ranging from 0.07 in Rwanda (2012) to 0.5 in Malawi (2013). The HIV rate ratio was pooled using random-effects model fitting data from countries with data collected over the period 2012-2019, including Kenya, Malawi, Rwanda, Tanzania, Uganda, Zambia and Zimbabwe, using the R package metafor.[13] The pooled ratio value is used to predict HIV prevalence in prevalent cases from HIV prevalence in notified cases in African countries that were not able to measure the prevalence of HIV among survey cases.

The above two methods to derive incidence from prevalence are compared in Table 3. It is not clear a priori which method will perform better. The second method requires a sufficient number
of cases on treatment at the time of the survey (as a rule of thumb, at least 30 cases) to generate relatively stable estimates. When both methods can be applied (so far only in selected low-HIV settings), results from two methods may be combined in a statistical ensemble approach as follows:

The incidence rate obtained using method \( i \) is assumed distributed Beta with shape and scale parameters \( \alpha_i+1 \) and \( \beta_i+1 \), respectively, and determined using the method of moments:

\[ I_i \sim B(\alpha_i+1, \beta_i+1) \]

so that

\[
Prob(x = TB) = \int_0^1 xB(\alpha_i, \beta_i) \, dx = \frac{\alpha_i + 1}{\alpha_i + \beta_i + 2}
\]

The combined probability is then expressed as

\[
Prob(x = TB) = \frac{\sum \alpha_i + 1}{\sum \alpha_i + \sum \beta_i + 2}
\]

\[
Var = \frac{(\sum \alpha + 1)(\sum \beta + 1)}{(\sum \alpha + \sum \beta + 2)^2(\sum \alpha + \sum \beta + 3)}
\]

Indirect estimation of incidence from prevalence relies on a number of assumptions difficult to verify, including (i) epidemic in a stable state of equilibrium; (ii) correctly assumed distribution of disease duration for each case category; (iii) size of the unmeasured prevalence of clinically diagnosed TB and childhood TB correctly estimated.

**Table 3. Estimates of incidence derived from prevalence survey results, based on two estimation methods.**

<table>
<thead>
<tr>
<th></th>
<th>Prevalence (10^{-3})</th>
<th>Incidence - Method 1 (10^{-3}y^{-1})</th>
<th>Incidence - Method 2 (10^{-3}y^{-1})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambodia 2002</td>
<td>12 (10-15)</td>
<td>4 (2.5-5.8)</td>
<td>2.2 (1.5-2.9)</td>
</tr>
<tr>
<td>Cambodia 2011</td>
<td>8.3 (7.1-9.8)</td>
<td>6.7 (4.5-9.3)</td>
<td>3.8 (2.2-5.8)</td>
</tr>
<tr>
<td>Myanmar 2009</td>
<td>6.1 (5-7.5)</td>
<td>3.3 (2-4.8)</td>
<td>3.5 (2-5.1)</td>
</tr>
<tr>
<td>Thailand 2012</td>
<td>2.5 (1.9-3.5)</td>
<td>2.3 (1-3.5)</td>
<td>1.1 (0.7-1.6)</td>
</tr>
</tbody>
</table>
Method 3 - Notifications in high-income countries adjusted by a standard factor to account for under-reporting and under-diagnosis

TB surveillance systems from countries in the high-income group and other selected countries in the upper-middle income group are assumed to perform similarly well on average in terms of under-diagnosis and under-reporting. Exceptions include the Republic of Korea, where the under-reporting of TB cases has recently been measured using annual inventory studies and France, where the estimated level of under-reporting was communicated by public health authorities, based on unpublished survey results. In the United Kingdom and the Netherlands, incidence was obtained using capture-recapture modeling (see next section). Surveillance data in this group of countries are usually internally consistent. Consistency checks include detection of rapid fluctuations in notification rates and in the ratio of TB deaths / TB notifications ($M/N$ ratio), which may be indicative of reporting problems.

Method 4 - Inventory studies, capture-recapture modelling

This method was used for 7 countries: China, Egypt,[14] Indonesia, Iraq,[15] the Netherlands,[16] the United Kingdom,[17] and Yemen.[18] Capture-recapture modelling is considered in studies with at least 3 sources (lists) and estimation of between source dependences.[9] The surveillance gap (proportion of unreported incident cases) in the United Kingdom and the Netherlands was assumed time invariant. In Yemen, trends in incidence were derived from results of two consecutive tuberculin surveys.[20] In Egypt, Indonesia and Iraq, trends were derived using methods described in section describing method 1.

Capture-recapture modelling for estimating TB incidence requires the following six assumptions: (i) all cases should be observable (preclinical stages are rarely detected before they become symptomatic); (ii) low proportion of mismatches and matching failures, which typically requires a large sampling fraction; (iii) closed population during the study period (typically 3-6 months); (iv) dependences between $S$ data sources ($S \geq 3$) accounted for in the model design but $S$-way interaction assumed null - referrals between sources (e.g. clinic to lab) may imply an $S$-way interaction, invalidating the approach (of note, in many high-burden countries, there will not be 3 sources meeting requirements); (v) homogeneity of within-source observation probabilities across subpopulation groups such as defined by socio demographic characteristics; (vi) consistent case
definitions across sources. It is anticipated that capture recapture may only be successfully implemented in very few high-burden countries planning an inventory study.

**HIV-positive TB incidence**

Provider-initiated testing and counselling with at least 50% HIV testing coverage is the most widely available source of information on the prevalence of HIV in TB patients. However, this source of data is affected by selection biases, particularly when coverage is closer to 50% than to 100%. As coverage of HIV testing continues to increase globally, biases will decrease. Other sources of information on the prevalence of HIV among new TB cases include sero-surveys of a random sample of newly diagnosed TB cases and HIV sentinel surveillance systems when they include TB as a sentinel group. The different data sources were combined using local polynomial regression fitting by weighted least squares, using weight values of 1 for data from a nationally representative survey, 0.2 for data based on HIV sentinel surveillance, and a value equal to testing coverage in the case of data from provider-initiated HIV testing with coverage greater than 50%, and zero weights when testing coverage was less than 50%. In countries with no surveillance data on HIV among TB cases, the prevalence of HIV was derived indirectly from the prevalence of HIV in the general population, based on the relationship between the prevalence of HIV in TB and the prevalence of HIV in the general population shown in Annex 2.
### 4. Mortality caused by TB, 2000-2019

The best sources of data about deaths from TB (excluding TB deaths among HIV-positive people) are vital registration (VR) systems in which causes of death are coded according to ICD-10 (although the older ICD-9 and ICD-8 classification are still in use in several countries), using ICD-10: A15-A19 and B90 codes, equivalent to ICD-9: 010-018, and 137. When people with AIDS die from TB, HIV is registered as the underlying cause of death and TB is recorded as a contributory cause. Since one third of countries with VR systems only report to WHO the underlying causes of death and not contributory causes, VR data usually cannot be used to estimate the number of TB deaths in HIV-positive people. Two methods were used to estimate TB mortality among HIV-negative people (see web content of WHO’s Global TB Report 2022, [figure 2.2.14](#)):  

- direct measurements of mortality from VR systems or mortality surveys;
- indirect estimates derived from multiplying estimates of TB incidence by estimates of the CFR.

#### Estimating TB mortality among HIV-negative people from vital registration data and mortality surveys up to 2019

As of July 2019, mortality data from 123 countries were used, representing 60% of the estimated number of TB deaths (among HIV-negative TB) globally in 2019.

Estimates for 21 countries, including India and for South Africa (adjusted for HIV/TB miscoding) were obtained from the Institute of Health Metrics and Evaluation at [http://ghdx.healthdata.org/gbd-results-tool](http://ghdx.healthdata.org/gbd-results-tool), readjusted to fit WHO mortality envelopes (the estimated number of deaths in total) by using a multiplication factor equal to the ratio of WHO to IHME envelopes. The median country-year envelope ratio (WHO/IHME) was 1.03 (interquartile range, 0.94-1.11) among 391 country-year data points.

Among the countries for which VR or mortality survey data could be used, there were 1586 country-year data points 2000–2019, after removing 120 country-year data points with insufficient data quality as estimated by WHO.[19]

Reports of TB mortality are adjusted upwards to account for incomplete coverage (estimated deaths with no cause documented) and ill-defined causes of death (ICD-9: B46, ICD-10: R00–
It is assumed that the proportion of TB deaths among deaths not recorded by the VR system was the same as the proportion of TB deaths in VR-recorded deaths. For VR-recorded deaths with ill-defined causes, it is assumed that the proportion of deaths attributable to TB is the same as the observed proportion in recorded deaths. The adjusted number of TB deaths \( \kappa_a \) is obtained from the VR report \( \kappa \) as follows:

\[
\kappa_a = \frac{\kappa}{v(1 - g)}
\]

where \( v \) denotes coverage (i.e. the number of deaths with a documented cause divided by the total number of estimated deaths) and \( g \) denotes the proportion of ill-defined causes. The uncertainty related to the adjustment was estimated as follows:

\[
\sigma = \frac{\kappa}{4v(1 - g) - 1}
\]

The uncertainty calculation does not account for miscoding, such as HIV deaths miscoded as deaths due to TB, except in South Africa.

Missing data between existing adjusted data points are interpolated. Trailing missing values are predicted using a Kalman smoother or using the last observation carried forward or in the case of leading missing values, the next observation carried backwards.

In 2019, 58% of global TB mortality (excluding HIV) was directly measured from VR or survey data (or imputed from survey or VR data from previous years). The remaining mortality was estimated using the indirect methods described in the next section.

**Estimating TB mortality among HIV-negative people from estimates of case fatality rates and TB incidence**

In countries lacking mortality data of the necessary coverage and quality, TB mortality is estimated as the product of TB incidence and the case fatality rate (CFR) after disaggregation by case type as shown in Table 4, following a literature review of CFRs by the TB Modelling and Analysis Consortium (TB-MAC):

\[
M^- = (I^- - T^-)f_u^- + T^-f_t^-
\]  (1)
where $M$ denotes mortality, $I$ incidence, $f_u$ and $f_t$ denote CFRs untreated and treated, respectively and the superscript denotes HIV status. $T$ denotes the number of treated TB cases. In countries where the number of treated patients that are not notified (under-reporting) is known from an inventory study, the number of notified cases is adjusted upwards to estimate $T$ accounting for under-reporting.

Table 4. Distribution of CFRs by case category

<table>
<thead>
<tr>
<th>CFR Sources</th>
<th>CFR</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not on TB treatment $f_u$</td>
<td>0.43 (0.28-0.53)</td>
<td>[20,21]</td>
</tr>
<tr>
<td>On TB treatment $f_t$</td>
<td>0.03 (0-0.07)</td>
<td>[22]</td>
</tr>
</tbody>
</table>

Estimating TB mortality among HIV-positive people

TB mortality among HIV-positive is calculated exchanging superscripts - with + (Eq. 1). The case fatality ratios were obtained in collaboration with the TB Modeling and Analysis Consortium (TB-MAC), and are shown in Table 5. The disaggregation of incident TB into treated and not treated cases is based on the numbers of notified cases adjusted for under-reporting.

Direct measurements of HIV-associated TB mortality are urgently needed. This is especially the case for countries such as South Africa and Zimbabwe, where national VR systems are already in place. In other countries, more efforts are required to initiate the implementation of sample VR systems as an interim measure.
Table 5. Distribution of CFR in HIV-positive individuals

<table>
<thead>
<tr>
<th>ART</th>
<th>TB treatment</th>
<th>CFR</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>off</td>
<td>off</td>
<td>0.78 (0.65-0.94)</td>
<td>[20]</td>
</tr>
<tr>
<td>off</td>
<td>on</td>
<td>0.09 (0.03-0.15)</td>
<td>[22,23]</td>
</tr>
<tr>
<td>&lt; 1 year</td>
<td>off</td>
<td>0.62 (0.39-0.86)</td>
<td>Data from review + assumptions</td>
</tr>
<tr>
<td>&lt; 1 year</td>
<td>on</td>
<td>0.06 (0.01-0.13)</td>
<td>Data from review + assumptions</td>
</tr>
<tr>
<td>≥ 1 year</td>
<td>off</td>
<td>0.49 (0.31-0.70)</td>
<td>Assumptions</td>
</tr>
<tr>
<td>≥ 1 year</td>
<td>on</td>
<td>0.04 (0.00-0.10)</td>
<td>Assumptions</td>
</tr>
</tbody>
</table>
5. Estimation of uncertainty, 2000-2019

There are many potential sources of uncertainty associated with estimates of TB incidence, prevalence and mortality, as well as estimates of the burden of HIV-associated TB and RR-TB. These include uncertainties in input data, in parameter values, in extrapolations used to impute missing data, and in the models used. Uncertainty in population estimates is not accounted for.

Notification data are of uneven quality. Cases may be under-reported (for example, missing quarterly reports from remote administrative areas are not uncommon), misclassified (in particular, misclassification of recurrent cases in the category of new cases is common), or over-reported as a result of duplicated entries in TB information systems or due to over-diagnosis. The latter issues can only be addressed efficiently in countries with case-based nationwide TB databases that include patient identifiers. Sudden changes in notifications over time are often the result of errors or inconsistencies in reporting.

Uncertainty bounds and ranges are defined as the 2.5th and 97.5th percentiles of outcome distributions. The general approach to uncertainty analyses is to propagate errors in $m$ real-valued random variables $X$ by approximating a function $h(X)$ using second-order Taylor series expansion about its moments.\[24\] Using matrix notation, the expected value $E[h(X)]$ and variance of $h(X)$ were approximated as follows:

\[
E[h(X)] \approx h(E[X]) + \frac{1}{2!} \text{tr} H(h) \Sigma(X)
\]

\[
\text{Var}(h(X)) \approx \nabla(h) \Sigma(X) \nabla(h)^T + \frac{1}{2!} \text{tr} \left( (H(h)) \Sigma(X) \right)^2
\]

where $\text{tr}$ denotes the trace, $H(h)$ the Hessian matrix of partial second-order derivatives of $h(X)$ with respect to each $X_i=1..m$, $\nabla(h)$ the gradient matrix of partial first-order derivatives and $\Sigma(X)$ the joint covariance matrix of $X$. 

New dynamic and statistical models were developed to produce estimates of TB incidence and mortality in 2020-2021 for certain countries. These new methods were required to produce estimates that account for the major disruptions to the provision of and access to TB diagnostic and treatment services that have occurred in the context of the COVID-19 pandemic. Compared to the methods used for the 2020 Global TB Report, this updated analysis includes: (i) a more streamlined modelling approach that allows, for example, modelling of countries that have both a large burden of HIV and a large private healthcare sector (ii) an increase in the number of countries modelled, from 16 to 28, and (iii) an updated approach for countries that were not individually modelled (region-specific models).

Estimates of TB incidence and mortality in all high-income countries in 2020 and 2021 were produced using the same methods as those used pre-2020; that is, notification data with a standard adjustment for incidence, and vital registration (VR) data for mortality. For low- and middle-income countries (LMIC) that were not modelled (i.e. those for which case notifications in 2020 and 2021 did not show a substantial reduction relative to pre-2020 trends), the methods used to estimate TB incidence and mortality before 2020 were retained for use in 2020 and 2021, with the assumption that pre-2020 trends continued in 2020 and 2021.

6.1 Country-specific dynamic models

The methodology was presented and reviewed at a meeting of a subgroup of the WHO Global Task Force on TB Impact Measurement in May 2022. More information is available in the background document prepared for the meeting and the meeting report.[25]

Dynamic country-specific models were developed for 28 countries (one was still under development at the time of publication of this report, and thus results for 27 were published). These countries – prioritized based on the size of their contribution to the global shortfall in TB case notifications between 2019 and 2020/2021 – are listed in Table 6 below. Collectively, they accounted for 95% of the drop in global TB notifications from January 2020 to December 2021.
inclusive. Countries for which pre-existing declining trends explained much of the decline in notifications in 2020 and 2021 were excluded (Ethiopia and South Africa).

**Model overview**

Figure 1 shows a schematic illustration of the model. Although certain transitions (such as self-cure) are omitted for simplicity, the figure serves to illustrate a key component of the modelling approach: the time-varying rate of transition from undetected TB, to being on TB treatment. This rate incorporates all stages leading up to treatment initiation, i.e. the initial patient delay before first care seeking; any diagnostic delay before being successfully diagnosed with TB; and any treatment delay before successfully initiating treatment. Rather than aiming to model disruptions in each of these stages separately, the analysis concentrated on the total delay across all of these stages. The term $k(t)$ controls how this delay is shaped during periods of disruption. As described below, the value of $k(t)$ was adjusted on a month-by-month basis in order to reproduce the monthly time series of notifications from each country, from January 2020 onwards (or quarterly data from Q1 2020, where monthly is unavailable).
Figure 1. Schematic illustration of the model structure

Figure 1 is a much-simplified version of the model, focusing on the key mechanism through which COVID-related disruptions are modelled (curved arrow at bottom of the figure). As described in the text, if pre-COVID rates of treatment initiation are given by the rate $d$, these rates were assumed to be modified by a time-dependent factor $k(t)$ during the pandemic, adjusted on a monthly (or quarterly) basis in order to match notification data. Additional model structure not shown, for simplicity, include the following: (i) The compartment ‘On TB treatment’ is split it into two to represent public and private sectors, with respective rates of initiation on treatment labelled $d_{pu}$ and $d_{pr}$. (ii) All model compartments are divided into three stata to represent HIV status: HIV-negative, HIV-positive but not on ART; and on ART. (iii) ‘Recovered’ compartments are stratified into three types: recovered after treatment completion (with low relapse risk); after treatment interruption or self cure (with high relapse risk); and long-term recovered (with minimal relapse risk). (iv) Other commonly incorporated transitions in TB natural history, not shown but present, include: self-cure, reinfection, and population turnover. See governing equations for the full model specification.

Model equations

The full model specification is as follows. In the following governing equations, the subscript $h$ denotes HIV status, with values 0, 1, 2 denoting respectively: those who are HIV-negative, those with HIV but on ART; and those on ART. The subscript $s$ denotes healthcare sectors, with values 0, 1 denoting respectively the public sector (including all non-public providers notifying TB), and the private (or non-notifying sector).
All state variables represent proportions of the population (rather than numbers). All model parameters are defined in Table 7. As described below, the function $f(\cdot)$ in each equation denotes transitions between HIV strata in the model.

Uninfected ($U$):

$$\frac{dU_h}{dt} = b - \epsilon_h \lambda U_h - \mu_h U_h + f(U_h)$$

Latent ‘fast’ infection ($L_h^{(fast)}$):

$$\frac{dL_h^{(fast)}}{dt} = \epsilon_h \lambda \left[ U_h + (1 - c_h)(L_h^{(slow)} + R_h^{(lo)} + R_h^{(hi)} + R_h^{(st)}) \right] - (u_h + v_h + \mu h)L_h^{(fast)} + f(L_h^{(fast)})$$

Latent ‘slow’ infection ($L_h^{(slow)}$):

$$\frac{dL_h^{(slow)}}{dt} = v_h L_h^{(fast)} - (w_h + \mu_h + \epsilon_h (1 - c_h) \lambda) L_h^{(slow)} + f(L_h^{(slow)})$$

Active, infectious disease ($I_h$):

$$\frac{dI_h}{dt} = u_h L_h^{(fast)} + w_h L_h^{(slow)} + \rho^{(lo)} R_h^{(lo)} + \rho^{(hi)} R_h^{(hi)} + \rho^{(st)} R_h^{(st)}$$

$$- \left[ k(t)(d_{pu} + d_{pr} + g(t)) + \sigma_h + \mu_h^{(TB)} \right] I_h + f(I_h)$$

On TB treatment in sector $s$ ($T_{hs}$):

$s = 0$: \hspace{0.5cm} \frac{dT_{h,0}}{dt} = k(t)d_0 I_h + k(t)g(t)I_h - \left( \tau + \delta + \mu_h^{(TB)} \right) T_{h,0} + f(T_{h,0})$

$s = 1$: \hspace{0.5cm} \frac{dT_{h,1}}{dt} = k(t)d_1 I_h - \left( \tau + \delta + \mu_h^{(TB)} \right) T_{h,1} + f(T_{h,1})$

Recovered, with high risk of relapse (self-cure or following treatment interruption):

$$\frac{dR_h^{(hi)}}{dt} = \sigma_h I_h + \delta T_{hs} - (\rho^{(hi)} + r + \mu_h + \epsilon_h (1 - c_h) \lambda) R_h^{(hi)} + f(R_h^{(hi)})$$
Recovered, with low risk of relapse (following treatment completion):

\[
\frac{dR_h^{(lo)}}{dt} = \tau T_{hs} - (\rho^{(lo)} + r + \mu_h + \epsilon_h(l - c_h)\lambda)R_h^{(lo)} + f(R_h^{(lo)})
\]

Recovered, long-term stabilised relapse risk:

\[
\frac{dR_h^{(st)}}{dt} = rR_h^{(hi)} + rR_h^{(lo)} - (\rho^{(st)} + \mu_h + \epsilon_h(l - c_h)\lambda)R_h^{(st)} + f(R_h^{(st)})
\]

Force-of-infection (\(\lambda\)):

\[
\lambda = \sum_h \beta_h I_h
\]

where \(\beta_h\) is the rate-of-infection associated with TB disease with HIV status \(h\). Because HIV positive TB can be less infectious than HIV-negative TB, \(\beta_I\) is expected to be lower in value than \(\beta_0\) and \(\beta_2\). Accordingly, it was assumed that \(\beta_0 = \beta_2 = m\beta_I\), for a parameter \(m\) to be calibrated, and constrained to be between 0 and 1.

In all the above equations, \(f(. )\) denotes transitions between HIV states. For any given state variable \(X_h\), it is defined as follows:

\[
f(X_h) = \begin{cases} 
-t_{HIV}X_0, & \text{if } h = 0 \\
t_{HIV}X_0 - r_{ART}X_1, & \text{if } h = 1 \\
r_{ART}X_1, & \text{if } h = 2 
\end{cases}
\]

where \(t_{HIV}\) denotes the per-capita rate of acquiring HIV, and \(r_{ART}\) denotes the per-capita rate of initiating ART.
Notifications in a time interval $\tau$ (for example, a month) are calculated using:

$$\int_{\tau} \left[ k(t) d_{pu} \sum_h I_h \right] dt$$

Finally, for simplicity the birth rate $b$ was chosen to maintain a constant population size, i.e.

$$b = \sum_h \mu_h \left[ U_h + L_h^{(fast)} + L_h^{(slow)} + T_{h0} + T_{hl} + R_{hl}^{(lo)} + R_{hl}^{(hi)} + R_{hl}^{(st)} \right] + \mu_h^{(TB)} I_h$$

**Implementation**

The model captures both HIV/TB coinfection, and settings where the private sector plays a strong role in the management of TB. In implementation, only the HIV/TB structure was used in countries where HIV +ve individuals accounted for at least 10% of TB incidence, in 2019. The public/private structure was used for countries belonging to the WHO PPM priority list (see ref. [26]), as well as countries from the WHO South-East Asia region having private sectors that are not part of this list. Table 6 lists countries by the model structure employed.

*Table 6. List of countries modelled, and the model structures employed*

<table>
<thead>
<tr>
<th>HIV/TB</th>
<th>Public/private</th>
<th>HIV/TB and public/private</th>
<th>Neither HIV/TB nor public/private</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil</td>
<td>Angola</td>
<td>Kenya</td>
<td>Azerbaijan</td>
</tr>
<tr>
<td>Colombia</td>
<td>Bangladesh</td>
<td>Thailand</td>
<td>Kazakhstan</td>
</tr>
<tr>
<td>Lesotho</td>
<td>Cambodia</td>
<td></td>
<td>Kyrgyzstan</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>China</td>
<td></td>
<td>Malaysia</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>India</td>
<td></td>
<td>Mexico</td>
</tr>
<tr>
<td></td>
<td>Indonesia</td>
<td></td>
<td>Mongolia a,b</td>
</tr>
<tr>
<td></td>
<td>Nepal</td>
<td></td>
<td>Peru</td>
</tr>
<tr>
<td></td>
<td>Pakistan</td>
<td></td>
<td>Romania</td>
</tr>
<tr>
<td></td>
<td>Philippines</td>
<td></td>
<td>Russian Federation</td>
</tr>
<tr>
<td></td>
<td>Myanmar</td>
<td></td>
<td>Timor Leste a</td>
</tr>
<tr>
<td></td>
<td>Viet Nam</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a These countries were selected for the regional model but were the sole countries in their respective regions (and hence were included in the list of countries for country-level modelling).

b The model for Mongolia is under development.
For countries where the HIV/TB structure is not needed, the parameters $\beta_h, u_h, v_h, w_h$ were all set equal to zero for $h \in [1,2]$, as well as parameters $r_{HIV}$ and $r_{ART}$. For countries where the public/private structure is not needed, the parameter $d_{pr}$ was set equal to zero.

To implement the model for a given set of parameters $\theta$, a perturbation to a disease-free equilibrium was first modelled, then simulating to endemic equilibrium. To account for programmatic and HIV-related factors that drive non-equilibrium trends in TB burden, the following approaches were adopted with the different model structures:

**HIV/TB structure:** The equilibrium phase of the simulation assumed no HIV and no ART. Starting from 1980, the introduction of HIV was then modelled by incorporating data for annual HIV incidence (through $r_{HIV}$). For simplicity ART scale-up (through $r_{ART}$) was approximated in a linear way, calibrating the per-capita rate of ART initiation in 2019 in order to match ART coverage in that year. Conservatively, it was assumed that there were no disruptions to HIV services during COVID-related lockdowns.

**Public/private structure:** The equilibrium phase of the simulation assumed no public TB services (i.e. $d_{pu} = 0$), consistent with conditions prior to the DOTS strategy (see e.g. Mandal et al, 2017[27]). The introduction of nationally coordinated TB services was then modelled by assuming a linear scale-up of $d_{pu}$ from 0 to its value in $\theta$, over the period from 2000 to 2009.

**All other countries:** While the changes described above provide a mechanistic basis for trends in each of the modelled countries, they are not applicable in settings such as the Russian Federation. Here, declines in TB burden are more likely due to a large recent expansion in screening for TB, resulting in an increase in case-finding. Consistent with these changes, for such countries - without substantial burden of HIV nor a sizeable private healthcare sector - the model incorporated a per-capita rate of ‘case-finding’ $g$, assumed to scale up linearly from 0 to its value in $\theta$, over the period from 2014 to 2019.
Data and calibration

The following WHO estimates from 2019 were used for different country categories:

Countries with high HIV/TB burden:
- Estimated incidence and mortality rates of HIV -ve TB in 2019, with uncertainty intervals
- Estimated incidence and mortality rates of HIV +ve TB in 2019, with uncertainty intervals
- Notification rate (all TB) in 2019
- Proportion of PLHIV on ART, all years upto 2019
- Prevalence of HIV, all years upto 2019

Countries with private sector:
- Estimated incidence and mortality in 2019, with uncertainty intervals
- Notifications in 2019

All other countries:
- Estimated incidence and mortality in 2014, with uncertainty intervals
- Estimated incidence and mortality in 2019, with uncertainty intervals
- Notifications in 2019

For each calibration target, beta distributions were fitted for proportions, and log-normal distributions for all other data; an overall log-likelihood term was then defined as the summation of the log-likelihoods corresponding to each relevant data element. Uniform distributions were mostly assumed for prior distributions for each of the parameter ranges shown in Table 7. One exception was in the case of countries with a private sector, where a prior beta distribution was posed for the proportion contribution of the public sector, to the overall numbers of TB patients receiving treatment. Without this constraint, for certain country models can assign implausibly high values to either \(d_{pu}\) or \(d_{pr}\), so that the private sector handles either a negligible minority or an overwhelming majority of TB treatment. A relatively broad prior was chosen for the proportion of TB treatment managed by the public sector, assuming 95% uncertainty intervals of 30% - 70%.
Markov-Chain Monte Carlo was used to sample from the posterior density, in particular using adaptive MCMC[28] to efficiently determine the covariate structure for the proposal distribution. For all model outputs, uncertainty intervals were estimated by evaluating the 2.5th, 50th and 97.5th percentiles of the posterior distribution.

**Modelling disruptions to TB services**

The analysis concentrated on delays to diagnosis and treatment initiation, ignoring disruptions to treatment continuity amongst those already on TB treatment, partly for lack of systematic data, but also because previous modelling analysis[29] suggests that these types of disruptions are likely to have a weaker effect on incidence, than disruptions to diagnosis and treatment initiation.

The intensity and duration of disruptions was informed by monthly notifications (quarterly where monthly data is unavailable), as reported to WHO. It was assumed that any reduction in notifications, compared to an extrapolation of pre-2020 trends, arises from delays to diagnosis and treatment initiations, rather than shortfalls in reporting. In turn, these delays may arise from patient-related factors (e.g. symptomatic patients being less willing or able to seek care during periods of anti-COVID restrictions), or from health system related factors (e.g. TB programmes having less diagnostic capacity or human resources than usual times). The model structure shown above is agnostic to either of these factors, as the whole patient care seeking journey is made implicit in the rates of treatment initiation, shown as $d_{pu}$ in figure 1.

Assuming that treatment initiations are a reasonable proxy for notifications, the number of notifications in a given month $n$ is:

\[
\text{Notifications in month } n = \sum_h \left[ \int_{n}^{(n+1)} k(t) d_{pu} I_h \, dt \right],
\]

where $I_h$ is the number of individuals having active, infectious disease in Figure 1, with HIV status $h$. Using the full transmission model, the monthly value of $k(t)$ was therefore adjusted in such a
way as to yield treatment initiations consistent with the monthly notification data. The timeseries for $k(t)$ determined in this way, then formed the basis for model projections for incidence.

**Lockdown-related reductions in TB transmission**

As much as lockdowns and social restrictions can control transmission of COVID-19, they may also have had similar effects on TB transmission. It was assumed that in any setting experiencing a country-wide lockdown, there was a temporary, $x\%$ reduction in TB transmission during that period of lockdown (with transmission returning to pre-lockdown levels as soon as restrictions were lifted). Given uncertainty about the strength of these effects in different settings, $x$ was drawn from a uniform probability distribution over the interval [25, 75]. For any country implementing subnational lockdowns, this reduction was scaled in proportion to the share of the country’s population undergoing those lockdowns.

**Aligning model projections with WHO uncertainty intervals**

Because model projections are presented as a continuation of pre-2020 WHO estimates, there is a need to ensure continuity with at least point and uncertainty intervals in 2019. This continuity does not necessarily occur automatically because by its nature, the model makes mechanistic links between incidence, mortality and other calibration targets. Thus, model-based posterior distributions for calibration targets can be narrower than the inputs provided by WHO estimates. The following step was therefore adopted, to inflate model-based uncertainty and ensure alignment of uncertainty intervals between WHO and model estimates in 2019, for all calibration targets.

A posterior sample is denoted $\theta_i^{(J)}$, where $i$ denotes each element of the parameter vector (e.g. rate of transmission, rate of initiation of treatment, etc) and $j$ enumerates the posterior sample (i.e. ranging from 1 to 250, having drawn 250 samples from the posterior density). Each such posterior sample then yields a timeseries of model outputs such as incidence, mortality, etc, denoted as $y_t^{(J)}$ for month $t$. Each value of this timeseries was related to its initial value $y_0^{(J)}$ as of December 2019 using a simple regression, as follows (dropping the superscript $j$ for clarity):
\[ y_t(\theta, y_0) = \beta_0 y_0 + \sum_{i=1}^\infty \beta_i(t) \theta_i \]

The coefficients \( \beta_i(t), i \geq 0 \) were estimated using simple multivariate linear regression, estimated independently at each time step \( t \).

Finally, WHO data in 2019 (divided by 12 to yield monthly rates) was denoted as \( Z_0 \). A lognormal distribution was fitted to the central estimates and 95\% uncertainty intervals for \( Z_0 \), with 250 samples being drawn from this distribution, denoting these samples as \( z_0^{(j)} \). Post-2019 monthly projections to 2019 WHO data, \( z_t^{(j)} \), were then estimated as:

\[ z_t(\theta, z_0) = \beta_0 z_0 + \sum_{i=1}^\infty \beta_i(t) \theta_i \]

where, as above, the superscript \( j \) has been dropped from all terms to aid clarity. At each time-point \( t \), uncertainty intervals were estimated using 2.5\% and 97.5\% percentiles, and central estimates using the 50\% percentile.

**Model limitations**

As with all models, this analysis has some important limitations to note. Principally, it was assumed that drops in notifications can be attributed entirely to delays to diagnosis and treatment initiation. Other mechanisms may also operate, including reductions in TB transmission. This analysis does not address the potential for sustained reductions in transmission, for example as a result of greater mask use, even after restrictions are lifted. Given the slow nature of TB transmission dynamics, any such transmission effects would be expected to manifest fully on the order of years, rather than months: in future, such mechanisms may be increasingly plausible for countries still showing reduced TB notifications years after their lockdowns.
This analysis also makes a range of simplifying assumptions: other possible types of service disruptions were ignored, including to preventive therapy, and to continuity of TB treatment. Sub-annual notification data is provided aggregated across all age groups, and so it is not possible to model differential disruptions by age. It was also not possible to model differential disruptions by HIV status. For example, it might be hypothesised that those already in HIV care may be more less likely to experience disruptions, given that they are already engaged in the healthcare system. However, analysis of annual data from 2020 and 2021 suggests that PLHIV did not systematically see less pronounced disruptions in TB diagnosis, than those without HIV (Figure 2). Finally, while this analysis focuses on TB services, it also ignores the potential adverse impact of the pandemic on broader TB determinants, such as undernutrition and poverty. Such factors may contribute still further to long-term increases in TB burden.

Figure 2. Comparison of disruptions in HIV+ve TB notifications alone (vertical axis), vs all TB notifications (horizontal axis)

In Figure 2, ‘disruptions’ are quantified simply as the ratio of notifications in 2020 or 2021, vs those in 2019. Each point represents a country where HIV coinfection accounts for >10% of TB incidence. These comparisons are performed on annual data because subannual data is not stratified by HIV status. The diagonal dashed line shows the level where HIV+ve disruptions would be equivalent to overall disruptions; if HIV+ve disruptions were systematically less severe, then most points would lie below this line. However, as illustrated by the figure, there appears to be no systematic bias in either direction.
Table 7. Definitions and values of model parameters

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Definition</th>
<th>Value (range)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\beta_h$</td>
<td>Average annual infections per TB case</td>
<td>$h = 0$ (HIV -ve) Calibrated to match epidemiological data, with uniform priors [0 - 30]</td>
<td></td>
</tr>
<tr>
<td>$h = 1$ (HIV+ve, not on ART) $h = 2$ (on ART)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$u_h$</td>
<td>Per-capita annual rate of progression to active TB from ‘fast’ latent infection</td>
<td>$h = 0$ (HIV -ve) $0.0826$ $(0.041, 0.12)$ Menzies (2018)[30], with uniform prior using intervals of $\pm 50%$</td>
<td></td>
</tr>
<tr>
<td>$h = 1$ (HIV+ve, not on ART) $u_1 = k_{LTI} u_{\phi}$, for $k_{LTI}$ to be calibrated to match HIV/TB incidence, with uniform ranges of [1 - 100]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$h = 2$ (on ART) $u_2 = u_1(0.4 − 0.24p)$, where $p$ is the coverage of IPT amongst those on ART, and assuming that ART and IPT independently have 60% effectiveness in reducing TB incidence. Formula derived as a weighted average (weighted by $p$) of progression rates depending on TPT status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$v_h$</td>
<td>Per-capita annual rate of stabilisation from latent ‘fast’ to latent ‘slow’ compartments</td>
<td>$h = 0$ (HIV -ve), $h = 2$ (on ART) $0.872$ $(0.44 − 1.3)$ Menzies (2018)[30], with uniform prior using intervals of $\pm 50%$</td>
<td></td>
</tr>
<tr>
<td>$h = 1$ (HIV+ve, not on ART) $0$ Assumption: without ART, PLHIV have no ‘stabilisation’ of progression risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parameter</td>
<td>Description</td>
<td>Reference</td>
<td>Details</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>$w_h$</td>
<td>Per-capita annual rate of reactivation to active TB from ‘slow’ latent infection</td>
<td>Menzies (2018)[30], with uniform prior using intervals of ± 50%</td>
<td>$h = 0$ (HIV -ve) $6 \times 10^{-4}$ ($3 \times 10^{-4}$ $- 9 \times 10^{-4}$) $h = 1$ (HIV +ve, not on ART) $w_l = k_{LTBI}w_0$, for $k_{LTBI}$ to be calibrated to match HIV/TB incidence, with uniform ranges [1 - 100] $h = 2$ (on ART) $w_2 = w_1(0.4 - 0.24p)$, where $p$ is the coverage of IPT amongst those on ART, and assuming that ART and IPT independently have 60% effectiveness in reducing TB incidence</td>
</tr>
<tr>
<td>$\mu_{h}^{(TB)}$</td>
<td>Per-capita annual rate of mortality, untreated TB</td>
<td>Tiemersma (2011)[21], with uniform prior using intervals of ± 50%</td>
<td>$h = 0$ (HIV -ve) $1/6$ (0.083, 0.25) $h = 2$ (on ART) $h = 1$ (HIV+ve, not on ART) $k_{mortality}\cdot\mu_{0}^{(TB)}$, for parameter $k_{mortality}$ calibrated to match HIV/TB mortality, with uniform ranges [1 – 10]</td>
</tr>
<tr>
<td>$\sigma_h$</td>
<td>Per-capita annual rate of spontaneous recovery</td>
<td>Tiemersma (2011)[21], with uniform prior using intervals of ± 50%</td>
<td>$h = 0$ (HIV -ve) $1/6$ (0.083, 0.25) $h = 2$ (on ART) $h = 1$ (HIV+ve, not on ART) $0$ Assumption</td>
</tr>
<tr>
<td>$c_h$</td>
<td>Protection from reinfection arising from prior exposure</td>
<td>Andrews (2012)[31], with uniform prior across range shown</td>
<td>$h = 0$ (HIV -ve) $[0.5 – 0.9]$ $h = 2$ (on ART) $h = 1$ (HIV+ve, not on ART) $0$ Assumption</td>
</tr>
<tr>
<td>$\epsilon_h$</td>
<td>Relative exposure to TB amongst those having HIV</td>
<td>Calibrated, with uniform prior across range shown</td>
<td>$h = 0$ (HIV-ve) $1$ (Reference) $h = 1$ (HIV+ve, not on ART) $[0 – 10]$ $h = 2$ (on ART) $[0 – 10]$</td>
</tr>
<tr>
<td>Parameter</td>
<td>Description</td>
<td>Reference and Prior Information</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>----------------------------------</td>
<td></td>
</tr>
<tr>
<td>$d_{pu}$</td>
<td>Per-capita annual rate of diagnosis and treatment initiation in the public sector, including all private providers notifying TB</td>
<td>Calibrated to match notification data</td>
<td></td>
</tr>
<tr>
<td>$d_{pr}$</td>
<td>Per-capita annual rate of diagnosis and treatment initiation in the private (non-notifying) sector</td>
<td>Calibrated with prior on proportion of TB treatment provided by private sector (i.e. $d_{pr}/(d_{pr} + d_{pu})$) having beta distribution with 2.5th, 97.5th percentiles respectively 0.3 and 0.7</td>
<td></td>
</tr>
<tr>
<td>$g(t)$</td>
<td>Per-capita annual rate of linkage to treatment, as a result of case-finding efforts (non-HIV, non-private sector countries only)</td>
<td>Incorporated to provide mechanistic basis for trends in countries without HIV or private sector. The parameter $g$ is assumed to increase in a linear way from 0 in 2014, to a value $g_{max}$ in 2019. The value of $g_{max}$ is calibrated to match incidence in 2014 and 2019, with uniform prior with range [0 – 10]</td>
<td></td>
</tr>
<tr>
<td>$k(t)$</td>
<td>COVID-induced reductions in rate of diagnosis and treatment initiation</td>
<td>Monthly (or quarterly) time series determined to match notification data</td>
<td></td>
</tr>
<tr>
<td>$\tau$</td>
<td>Per-capita annual rate of first-line treatment completion</td>
<td>2</td>
<td>Corresponding to standard treatment duration of 6 months</td>
</tr>
<tr>
<td>$\delta$</td>
<td>Per-capita annual rate of treatment interruption</td>
<td>Adjusted to match treatment completion rates</td>
<td>Country programme data</td>
</tr>
<tr>
<td>$\rho^{(lo)}$</td>
<td>Per-capita annual rate of relapse in first two years after treatment completion</td>
<td>0.032 (0.016 – 0.048)</td>
<td>Romanowski (2019)[32], Menzies (2009)[33] and Weis (1994)[34], with uniform prior using intervals of ± 50%</td>
</tr>
<tr>
<td>$\rho^{(hi)}$</td>
<td>Per-capita annual rate of relapse in first two years after self-cure or incomplete treatment</td>
<td>0.14 (0.07 – 0.21)</td>
<td></td>
</tr>
<tr>
<td>$\rho^{(st)}$</td>
<td>Per-capita annual rate of relapse &gt;two years after last TB episode</td>
<td>0.0015</td>
<td>Most relapse occurs in first two years after recovery: Guerra-Assuncao (2015)[35]</td>
</tr>
<tr>
<td>$r$</td>
<td>Per-capita annual rate of ‘stabilising’ from high to low relapse risk</td>
<td>0.5</td>
<td></td>
</tr>
</tbody>
</table>
### Demographics

<table>
<thead>
<tr>
<th>$\mu_h$</th>
<th>Per-capita background annual mortality hazard, in absence of TB</th>
<th>$h = 0$ (HIV -ve), $h = 2$ (on ART)</th>
<th>1/Mean lifespan $\frac{1}{\mu}$</th>
<th>$h = 1$ (HIV+ve, not on ART)</th>
<th>Calibrated to yield HIV prevalence</th>
<th>HIV prevalence estimates from Thembisa model[36]</th>
</tr>
</thead>
</table>

### 6.2 Region-specific dynamic models

In addition to the 28 countries listed in Table 6, there were several countries that had seen substantial disruptions, but did not contribute sufficiently to the global burden to be incorporated into the country-specific modelling. These 26 countries were modelled at the level of their respective WHO regions, as follows.

Countries selected for the regional modelling were those fulfilling the following criteria: (i) non-high income countries that were not included in Table 6, and (ii) that saw $>10\%$ reductions in notifications in 2020 and 2021 compared to 2019. Countries were excluded if these reductions could be explained by an extension of pre-2020 trends (this was the case for Georgia only). Table 8 below lists these countries, and the WHO regions to which they belong.

For each region, all country data were aggregated to the regional level weighted by population size. The modelling described above was then applied to each region, to capture incidence and mortality projections at the regional level. Finally, to create country-level projections, it was assumed that incidence in year $t$, relative to that in 2019, was the same for a given region as for all countries within that Region. Thus model-based incidence projections at the Regional level were extrapolated to the country level, and similarly for mortality projections.
Table 8. Countries modelled as regional aggregations, by WHO region

<table>
<thead>
<tr>
<th>Africa</th>
<th>The Americas</th>
<th>South-East Asia</th>
<th>Europe</th>
<th>Eastern Mediterranean</th>
<th>Western Pacific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botswana</td>
<td>Argentina</td>
<td>Timor-Leste a</td>
<td>Albania</td>
<td>--</td>
<td>Mongolia a</td>
</tr>
<tr>
<td>Namibia</td>
<td>Belize</td>
<td></td>
<td>Armenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swaziland</td>
<td>Bolivia</td>
<td></td>
<td>Belarus</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Costa Rica</td>
<td></td>
<td>Montenegro</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cuba</td>
<td></td>
<td>Republic of Moldova</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dominican Republic</td>
<td></td>
<td>Serbia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ecuador</td>
<td></td>
<td>Tajikistan</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grenada</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guatemala</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guyana</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Honduras</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jamaica</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nicaragua</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paraguay</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suriname</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Venezuela</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Timor-Leste and Mongolia are the only eligible countries in their respective regions; thus, country-specific models were applied to these countries as described in section 7.1.
7. Disaggregation of TB incidence and mortality by age and sex, 2021

TB incidence

Estimates for men (males aged ≥15 years), women (females aged ≥15 years) and children (aged <15 years) are derived as follows. Age and sex disaggregation of smear-positive TB case notifications has been requested from countries since the establishment of the data collection system in 1995, but with few countries actually reporting these data to WHO. In 2006, the data collection system was revised to additionally monitor age-disaggregated notifications for smear-negative and extrapulmonary TB. The revision also included a further disaggregation of the 0–14 age group category to differentiate very young children (0–4 years) from older children (5–14 years). While reporting of age-disaggregated data was limited in the early years of the data collection system, reporting coverage continued to improve. For 2012 case notifications, age-specific data reached 99%, 83% and 83% of total smear-positive, smear-negative and extrapulmonary tuberculosis global case notifications, respectively. Finally in 2013, another revision of the recording and reporting system was necessary to allow for the capture of cases diagnosed using WHO-approved rapid diagnostic tests (such as Xpert MTB/RIF).[38] This current revision requests the reporting of all new and relapse case notifications by age and sex.

While there are some nationwide surveys that have quantified the amount of under-reporting of cases diagnosed in the health sector outside the network of the NTPs,[14,16,39] none have produced precise results by age. Small-scale, convenience-sample studies indicate that under-reporting of childhood TB can be very high[40,41] but extrapolation to national and global levels has not yet been possible. Producing estimates of TB incidence among children remains challenging primarily due to diagnostic challenges and the lack of age-specific, nationwide, robust survey and surveillance data.

In order to maintain consistency with total TB incidence and its uncertainty, the approach to estimating TB incidence by age and sex sought to disaggregate total incidence into incidence for each age group and sex. For countries where incidence was based on either a capture-recapture study or a standard factor adjustment of notification, and the implied case detection ratio was over
85%, we disaggregated total TB incidence by age and sex in proportion to case notifications. For these countries, surveillance systems were assumed to function well enough to inform patterns by age and sex directly. We also disaggregated incidence in proportion to case notifications in countries where fewer than 1,000 TB cases were reported in total. In these countries, there may be marked variability and modelled estimates are less appropriate.

For other countries, one million samples were drawn from a country ‘prior’ for the proportion of incidence in each age and sex group. Samples were accepted if they resulted in incidence exceeding notifications in every age and sex category. Where no samples were accepted, the 100 samples with the smallest undershoot were accepted. Final incidence estimates were based on the mean over accepted samples.

The prior for each country for adults was based on a hierarchical analysis for prevalence risk ratios which was developed based on TB prevalence survey data and Horton et al’s systematic review of prevalence sex ratios.[42] This prior closely followed age and sex patterns for TB prevalence in countries with surveys, and made predictions (with greater uncertainty) for countries without prevalence surveys. The prior for children was based on a mathematical modelling approach that simulates the course of natural history of TB in children, starting from estimates of TB infection in children as a function of demographic and adult TB prevalence, and subsequently modelling the progression to pulmonary and extra-pulmonary TB disease taking into account country-level BCG vaccination coverage and HIV prevalence.[43] The disaggregation by sex in children was based on a random-effects meta-analysis of the sex ratio in notification data for children (0-14 years).

Finally, for a small number of countries the approach above generated results that lacked face validity and a standard adjustment factor was applied to notifications instead.

**TB mortality**

TB mortality is disaggregated by age and sex using the age- and sex-specific adjusted (for coverage and ill-defined causes) number of deaths from VR data in countries with high-quality vital registration systems in place (ie, where these data have been used to estimate the TB mortality envelope).[37] For other countries, adult mortality is disaggregated by age, sex and HIV-infection
status by applying CFRs to disaggregated incidence estimates, distinguishing CFR by anti-TB treatment status and HIV/ART status (see Tables 4 and 5). TB mortality in children for these countries is also estimated from TB incidence in children using a case-fatality based approach.[44] This approach distinguishes case fatality in children by age, anti-TB treatment status, and HIV/ART status. HIV-positive TB deaths in adults are distributed by age and sex proportional to age- and sex-specific HIV prevalence from UNAIDS estimates in such a way as to maintain the estimated total number of HIV-positive TB deaths.
8. Drug-resistant TB - incidence and proportions with resistance

Proportions of new and previously treated TB cases with rifampicin resistance

Previous WHO Global TB Reports included estimates of drug resistance for the latest calendar year only. New methods were developed in 2022 to allow the production of time series of estimates for the period 2015–2021. The time series are for the proportions of TB cases (new and previously treated) that have rifampicin-resistant (RR) TB and the absolute number of incident RR-TB cases, of which multidrug-resistant (MDR) TB is a subset. The methodology was presented and reviewed at a meeting of a subgroup of the WHO Global Task Force on TB Impact Measurement in May 2022. More information is available in the background document prepared for the meeting and the meeting report.[25]

All surveys conducted according to WHO guidance[45] as well as all routine surveillance data meeting quality thresholds from 2000-2021 were used to inform the model. For routine surveillance data to be considered representative for new patients, two criteria must be met: (i) at least 80% of notified new pulmonary bacteriologically-confirmed TB cases must have a documented drug susceptibility testing result for at least rifampicin, and (ii) the ratio of pulmonary bacteriologically-confirmed TB cases classified as new versus unknown treatment history must be at least 4:1. For data from routine surveillance to be considered representative for previously treated patients, at least 80% of notified retreatment pulmonary bacteriologically-confirmed TB cases must have a documented drug susceptibility testing result for at least rifampicin.

Briefly, hierarchical regression models within a Bayesian paradigm were considered, and the best performing model selected for use. The data likelihood treats surveillance data as multinomial count data; estimates of RR-TB prevalence among TB cases derived from surveys are considered to be distributed log-normal with known precision.

Models consider intercept and linear trends on an abstract space that is mapped to the observed prevalences of resistance using a softmax transformation. Intercepts and trends are modelled through multivariate regressions for each patient group (new and previously treated), with regions used as covariates (the regions used are the six WHO regions plus a grouping of the former
republics of the Soviet Union, totaling 7 categories). The modelling choices explored related to the approach for modelling random effects (i.e. the hierarchical elements), with the final model using Leroux conditional autoregressive priors for both the intercept and trend, separately for new and retreatment patients. This class of model makes use of a spatial structure, with estimates for neighboring countries with imprecise or missing data being more strongly informed by nearby countries than distant ones. Models were fitted with MCMC using Stan.[46]

The models estimate the prevalence of resistance for 215 countries and territories for the years 2015-2021. The hierarchical nature of these models means that the learned distributions of random effects together with regression covariates (time and region) allow predictions of prevalence to be made for country-years without data, and for the uncertainty of estimates to respond to data, but with some degree of smoothing over temporal fluctuations. The selected model will be refitted over all years of data in future estimation rounds, generating revised estimates for the whole time series of prevalence estimates.

**Incidence of RR-TB**

To estimate the incidence of MDR/RR-TB, the same approach as previous years was adapted to include the time-dependence in the estimated proportions of new ($p_n$) and retreated ($p_r$) patients with MDR/RR-TB:

1. Estimate the proportion $r$ of relapses out of the sum of new and relapse cases;
2. Estimate $f$ the cumulative risk for incident cases to receive a non-relapse retreatment (retreatment following previous treatment failure or return after default);
3. Approximate RR incidence as:

   \[ I_{rr}(t) = I(t) \times \left[ (1-f)p_n(t) \left( (1-r) + rp \right) + f p_r(t) \right] \]

where $t$ is the year, $I(t)$ is total TB incidence, and $\rho$ is the risk of MDR/RR-TB in relapses relative to previously untreated cases.
$f$ may be estimated based on reported counts of cases disaggregated by treatment history over the most recent years.

**Proportion of RR-TB cases with resistance to fluoroquinolones (pre-XDR-TB)**

All surveys conducted according to WHO guidance as well as all routine surveillance data meeting quality thresholds from the previous 15 years (2007-2021) were used. For data from routine surveillance to be considered representative for fluoroquinolone resistance among MDR/RR-TB patients, the two criteria described above for rifampicin must be met. Additionally, at least 80% of MDR/RR-TB cases must have a documented drug susceptibility testing result for at least one fluoroquinolone. The average proportion of MDR/RR-TB cases with fluoroquinolone resistance is calculated by taking the ratio of identified fluoroquinolone-resistant cases among tested MDR/RR-TB cases. Errors are assumed to be binomial. The proportions of fluoroquinolone resistance were then pooled using country-specific estimates of MDR/RR-TB incidence as weights to generate a global estimate.
9. Drug-resistant TB - mortality

The VR mortality data reported to WHO by Member States do not differentiate between drug-resistant and drug-susceptible TB as a cause of death (there is no specific ICD-9 or ICD-10 codes for MDR/RR-TB, although some countries such as South Africa have allocated two specific codes U51 and U52 to classify deaths from MDR-TB and XDR-TB respectively).[47] Therefore, a systematic review and meta-analysis of the published literature was undertaken to estimate the odds ratio of dying from MDR-TB compared with non MDR-TB. We are assuming this odds ratio of death is the same as that for RR-TB. The global estimate of MDR/RR-TB deaths is based on the following formula:

\[ m = M \cdot p \cdot r \div (1-p + p \cdot r) \]

Where:

\( m \) = global MDR/RR-TB mortality,

\( M \) = global TB mortality,

\( p \) = overall proportion of MDR/RR-TB among prevalent TB cases, approximated by the weighted average of the proportion of new and retreated cases that have MDR/RR-TB,

\( r \) = the odds ratio of dying from MDR/RR-TB versus non-MDR/RR-TB.
10. Deaths averted by TB interventions

To estimate the number of deaths averted by TB interventions from 2000-2021, the actual numbers of TB deaths can be compared with the number of TB deaths that would have occurred in the absence of TB treatment (and without ART provided alongside TB treatment for HIV-positive cases). The latter number can be estimated conservatively as the number of estimated incident cases multiplied by the relevant estimated CFR for untreated TB. The CFR is calculated based on the combined total of deaths in HIV-negative and HIV-positive people for the purpose of cross-country comparisons; in particular, to illustrate the high CFRs in African countries, which could be reduced by effective detection and care programmes. CFRs restricted to HIV-negative TB deaths and cases can also be calculated but are not shown here. At the subnational level, CFRs can also be restricted to HIV-negative TB deaths, depending on the country and its HIV burden.

The estimate of the number of deaths averted is conservative because it does not account for the impact of TB services or availability of ART on the level of TB incidence; it also does not account for the indirect, downstream impact of these interventions on future levels of infections, cases and deaths.
11. Household contacts of bacteriologically confirmed pulmonary TB aged under 5 years and eligible for TB preventive therapy (TPT)

In low TB burden countries (116 high-income or upper middle-income countries with an estimated incidence rate less than 100 per 100 000 population), the number of household contacts aged under 5 years and eligible for TPT is defined as the number of children aged under 5 years who are household contacts of bacteriologically confirmed pulmonary TB cases and who have a positive result to testing for TB infection. In high TB burden countries, the number eligible is defined as the number of children under 5 years of age who are household contacts of bacteriologically confirmed pulmonary TB cases and who are not found to have active TB on appropriate clinical evaluation, without the requirement to test for TB infection.[48,49]

The estimated number \( n \) of household contacts aged under 5 years and eligible for TPT is

\[
n = \frac{b}{c} H p L (1 - t)
\]

where \( b \) is the number of notified bacteriologically confirmed pulmonary TB, \( c \) is the average number of TB cases per household, \( H \) is the average household size, \( p \) is national proportion of children aged under 5 years, \( t \) is proportion of household contacts aged under 5 years with active TB, and \( L \) is prevalence of TB infection among household contacts aged under 5 years (Table 9).

In high TB burden countries, \( L \) is set to 1 (testing for TB infection is not required). The following sources of uncertainty are accounted for: prevalence of TB infection, variance in the number of TB cases per household, and variance in the proportion of household contacts aged under 5 years with active TB. Uncertainty about United Nations Population Division (UNPD) population size is not documented. Errors were propagated using methods described in Chapter 5.
<table>
<thead>
<tr>
<th>Parameters</th>
<th>Values</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of notified bacteriologically confirmed pulmonary TB in 2021</td>
<td>Differ by country</td>
<td>WHO global TB database</td>
</tr>
<tr>
<td>National proportion of children aged &lt;5 years in 2022</td>
<td>Differ by country</td>
<td>2022 Revision of World Population, United Nations Population Division (<a href="https://esa.un.org/unpd/wpp/">https://esa.un.org/unpd/wpp/</a>)</td>
</tr>
<tr>
<td>National average household size</td>
<td>Differ by country</td>
<td>National censuses, DHS statistical year books, or official websites of the national statistical authorities</td>
</tr>
<tr>
<td>Prevalence of TB infection among child household contacts aged &lt;5 years in LBC</td>
<td>Constant across countries = 27.6% (19.2%-38.0%)</td>
<td>Systematic review of literature from LBC up to Dec 2015 (unpublished)</td>
</tr>
<tr>
<td>Average cluster size of active TB per household</td>
<td>Constant across countries =1.06 (95%CI 1.04-1.08)</td>
<td>Systematic review of literature between Jan 2005 and Dec 2015 (unpublished)</td>
</tr>
<tr>
<td>Proportion of children aged &lt;5 years with active TB among those who had a household contact with TB cases</td>
<td>Constant across countries =6.1% (95%CI 1.0%-16.3%)</td>
<td>Dodd et al, Lancet Glob Health. 2014[43]</td>
</tr>
</tbody>
</table>
12. Attributable risk for TB

The TB epidemic is strongly influenced by five risk factors: undernourishment, HIV infection, alcohol use disorders, smoking (especially among men) and diabetes (Table 10).

Risk ratios

Separate meta-analyses were performed to estimate the relative risks (RR) and their 95% confidence interval (95%CI), for undernourishment, alcohol use disorders, smoking and diabetes. The RR and 95%CI for HIV infection was calculated from the estimated incidence of TB in HIV-positive and HIV-negative people using the following formula

\[ RR_{HIV} = \frac{CI_{HIV+}}{CI_{HIV-}} \]

where \( CI_{HIV+} \) is the estimated incidence of TB among HIV-positive people in 2021 and \( CI_{HIV-} \) is the estimated incidence of TB among HIV-negative people in 2021.

Standard deviation for \( RR_{HIV} \) was computed using the second-order Taylor expansion formula.

Exposed population

The total exposed population was calculated as the product of the total population in 2021 (for undernourishment and HIV infection) or the adult population in 2021 (for alcohol use disorders, smoking and diabetes) and the proportion of the population affected by the corresponding risk factor \( P_e \).

Population attributable fraction

The population attributable fraction (PAF) is the proportion of incident TB cases in a population that is attributable to a given risk factor, and was calculated using the following formula:

\[ PAF = \frac{P_e(RR - 1)}{1 + P_e(RR - 1)} \]

Attributable TB cases

The attributable incidence rate in 2021 and its standard deviation were estimated using the second-order Taylor expansion formula as the product of the incidence rate of TB in the total population (for undernutrition and HIV infection) or the adult population (for alcohol use disorders, smoking
and diabetes) and the \( PAF \). The estimated number of attributable TB cases was then calculated as the product of the attributable incidence rate and the total population (for undernourishment and HIV infection) or the adult population (for alcohol use disorders, smoking and diabetes).

Table 10. Attributable risk for TB

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Relative risk (uncertainty interval)</th>
<th>Exposed population (millions)</th>
<th>PAF (%)</th>
<th>Attributable TB cases (millions, uncertainty interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol use disorders [50]</td>
<td>3.3 (2.1-5.2)</td>
<td>292</td>
<td>8</td>
<td>0.74 (0.50-1.0)</td>
</tr>
<tr>
<td>Diabetes [51]</td>
<td>1.5 (1.3-1.8)</td>
<td>498</td>
<td>3.1</td>
<td>0.37 (0.27-0.49)</td>
</tr>
<tr>
<td>HIV infection [52]</td>
<td>16 (14-18)</td>
<td>38</td>
<td>6.6</td>
<td>0.86 (0.70-1.0)</td>
</tr>
<tr>
<td>Smoking [53]</td>
<td>1.6 (1.2-2.1)</td>
<td>981</td>
<td>6.7</td>
<td>0.69 (0.49-0.92)</td>
</tr>
<tr>
<td>Undernourishment [54]</td>
<td>3.2 (3.1-3.3)</td>
<td>711</td>
<td>17</td>
<td>2.2 (2.0-2.3)</td>
</tr>
</tbody>
</table>
13. Conclusion

The methods described here can be combined to assess tuberculosis incidence and mortality, to evaluate progress towards targets for TB control and the Sustainable Development Goals (SDGs) for TB. Alternative TB burden estimation methods have been developed by the Institute of Health Metrics and Evaluation,[55] with generally consistent results at the global level compared with WHO, but with marked differences in specific countries. Discrepancies in estimates from different agencies reflect the questionable quality and completeness of the underlying data. Further convergence in estimates will result from improvements in measurements at country level. National TB programmes should be able to measure the level and time trends in incidence through well-performing TB surveillance with universal access to healthcare. In countries with incomplete routine surveillance, prevalence surveys of TB disease provide estimates of TB burden that do not heavily rely on expert opinion. The performance of TB surveillance should be assessed periodically[10] and the level of under-reporting should be measured[9] and minimized. TB mortality will ideally be measured by counting deaths in a comprehensive vital registration system.

WHO’s post-2015 global TB strategy, known as the End TB Strategy,[56] has the goal of ending the global TB epidemic, with corresponding targets of a 90% reduction in TB deaths and an 80% reduction in the TB incidence rate by 2030, compared with 2015. However, the milestones set for 2020 were still far from being achieved in 2021. The COVID-19 pandemic has caused enormous health, social and economic impacts since 2020. This includes impacts on the provision of and access to essential TB services, the number of people diagnosed with TB and notified as TB cases through national disease surveillance systems, and TB disease burden (incidence and mortality). Intensified efforts and increased funding are urgently needed to reverse the negative impact of the pandemic.
Acknowledgements

Ibrahim Abubakar, Sandra Alba, Elisabeth Allen, Martien Borgdorff, Jaap Broekmans, Ken Castro, Frank Cobelens, Ted Cohen, Charlotte Colvin, Sarah Cook-Scalise, Liz Corbett, Simon Cousens, Katherine Fielding, Peter Godfrey-Faussett, Yohhei Hamada, Rein Houben, Helen Jenkins, Avinash Kanchar, Li Liu, Mary Mahy, Valérie Schwoebel, Cherise Scott, James Seddon, Babis Sismanidis, Andrew Thomson, Edine Tiemersma, Hazim Timimi, Theo Vos, Emilia Vynnycky and Richard White reviewed the described methods to derive TB incidence, prevalence and mortality with disaggregation by age and sex for the period of 2000-2019 and provided specific recommendations to improve them. Nicholas A. Menzies, Hsien-Ho Lin and Finn McQuaid provided critical review of the initial transmission dynamic modelling to estimate the impact of COVID-19-related disruptions on TB incidence and mortality. Members of a subgroup of the WHO Task Force on TB Impact Measurement reviewed methodological updates to the dynamic modelling as well as new methods for generating the time series of RR-TB in a meeting held in Geneva in May 2022. The subsequent in-depth review provided by Nicholas A. Menzies, Finn McQuaid, Roel Baker and Richard White provided valuable further contributions.
Annex 1 - Definitions

**Incidence** is defined as the number of new and recurrent (relapse) episodes of TB (all forms) occurring in a given year. Recurrent episodes are defined as a new episode of TB in people who have had TB in the past and for whom there was bacteriological confirmation of cure and/or documentation that treatment was completed.

**Prevalence** is defined as the number of TB cases (all forms) at the middle of the year.

**Mortality** from TB is defined as the number of deaths caused by TB in HIV-negative people occurring in a given year, according to the latest revision of the International classification of diseases (ICD-10). TB deaths among HIV-positive people are classified as HIV deaths in ICD-10. For this reason, estimates of deaths from TB in HIV-positive people are presented separately from those in HIV-negative people.

The **case fatality rate** is the risk of death from TB among people with active TB disease.

The **case notification** rate refers to new and recurrent episodes of TB notified for a given year. Patients reported in the *unknown history* category are considered incident TB episodes (new or recurrent).

**Population estimates** were obtained from the World Population Prospects, which is produced by the United Nations Population Division (UNPD, http://esa.un.org/unpd/wpp/). The UNPD estimates sometimes differ from those made by countries.
Annex 2 - Relationship between HIV prevalence in new TB cases and HIV prevalence in the general population, 2000-2019

Let $I$ and $N$ denote incident cases and the total population, respectively, superscripts + and - denote HIV status, $\vartheta$ is the prevalence of HIV among new TB cases, $h$ is the prevalence of HIV in the general population and $\rho$ is the incidence rate ratio (HIV-positive over HIV-negative).

\[
\rho = \frac{I^+ / N^+}{I^- / N^-} > 1
\]

\[
\rho I^- = N^- / N^+
\]

\[
\rho \frac{I - I^+}{I^+} = \frac{N - N^+}{N^+}
\]

\[
\frac{I^+}{I} = \frac{\rho N^+}{I + (\rho - 1) \frac{N^+}{N}} = \vartheta
\]

\[
\vartheta = \frac{h \rho}{I + h(\rho - 1)}
\]

The TB incidence rate ratio $\rho$ can be estimated by fitting the following linear model with a slope constrained to 1

\[
\log(\beta) = \log\left(\frac{\vartheta}{I - \vartheta}\right) - \log\left(\frac{h}{I - h}\right), (\vartheta, h) \in [0, 1]
\]
References


52. The Global Health Observatory [Internet]. [cited 2022 Nov 23]. Available from: https://www.who.int/data/gho


